Esperion Therapeutics Inc. (NASDAQ:ESPR) has been given a $13.00 price objective by Chardan Capital in a research report issued to clients and investors on Thursday. The firm presently has a a “hold” rating on the biopharmaceutical company’s stock. Chardan Capital’s price target suggests a potential upside of 5.52% from the company’s current price.
Other equities analysts have also issued research reports about the company. JMP Securities reissued a “buy” rating and issued a $67.00 target price on shares of Esperion Therapeutics in a research report on Thursday, June 16th. Vetr lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 target price for the company. in a research report on Monday, July 18th. Citigroup Inc. reissued a “buy” rating and issued a $22.00 target price (down previously from $36.00) on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. Lake Street Capital cut their price target on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, June 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $25.00 price target (down from $77.00) on shares of Esperion Therapeutics in a research note on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $28.54.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 5.28% during midday trading on Thursday, hitting $12.97. 1,228,796 shares of the stock were exchanged. The stock’s market cap is $292.47 million. Esperion Therapeutics has a 52-week low of $9.58 and a 52-week high of $30.41. The firm’s 50 day moving average price is $12.23 and its 200-day moving average price is $13.99.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. During the same period in the previous year, the business posted ($0.55) earnings per share. On average, equities research analysts expect that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BVF Inc. IL acquired a new position in Esperion Therapeutics during the first quarter valued at $10,261,000. Senzar Asset Management LLC acquired a new position in Esperion Therapeutics during the second quarter valued at $2,171,000. FNY Managed Accounts LLC acquired a new position in Esperion Therapeutics during the second quarter valued at $1,976,000. A.R.T. Advisors LLC increased its position in Esperion Therapeutics by 93.6% in the first quarter. A.R.T. Advisors LLC now owns 200,858 shares of the biopharmaceutical company’s stock valued at $3,396,000 after buying an additional 97,112 shares during the last quarter. Finally, Pentwater Capital Management LP increased its position in Esperion Therapeutics by 6.6% in the second quarter. Pentwater Capital Management LP now owns 1,518,000 shares of the biopharmaceutical company’s stock valued at $14,998,000 after buying an additional 94,000 shares during the last quarter. Institutional investors and hedge funds own 65.22% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.